Truist reiterates Edgewise Therapeutics stock rating on phase 2 data

Truist reiterates Edgewise Therapeutics stock rating on phase 2 data

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.